Centaurus Financial Inc. Sells 624 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Centaurus Financial Inc. lessened its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 23.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,053 shares of the medical equipment provider’s stock after selling 624 shares during the quarter. Centaurus Financial Inc.’s holdings in Intuitive Surgical were worth $1,009,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in ISRG. Alpha DNA Investment Management LLC purchased a new stake in Intuitive Surgical in the third quarter worth approximately $719,000. Larson Financial Group LLC boosted its stake in shares of Intuitive Surgical by 79.4% in the 3rd quarter. Larson Financial Group LLC now owns 854 shares of the medical equipment provider’s stock valued at $420,000 after purchasing an additional 378 shares in the last quarter. Swedbank AB grew its holdings in shares of Intuitive Surgical by 1.7% during the 3rd quarter. Swedbank AB now owns 180,043 shares of the medical equipment provider’s stock valued at $88,450,000 after purchasing an additional 2,944 shares during the last quarter. Algert Global LLC purchased a new position in Intuitive Surgical in the 3rd quarter worth $1,988,000. Finally, Cerity Partners LLC lifted its stake in Intuitive Surgical by 10.5% in the third quarter. Cerity Partners LLC now owns 139,175 shares of the medical equipment provider’s stock worth $68,372,000 after purchasing an additional 13,188 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insiders Place Their Bets

In related news, insider Jamie Samath sold 22,903 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $525.00, for a total transaction of $12,024,075.00. Following the transaction, the insider now owns 8,757 shares in the company, valued at $4,597,425. This represents a 72.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Gary S. Guthart sold 18,151 shares of the stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $511.63, for a total value of $9,286,596.13. Following the transaction, the chief executive officer now directly owns 24,219 shares in the company, valued at $12,391,166.97. The trade was a 42.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,539 shares of company stock valued at $26,112,364. Corporate insiders own 0.80% of the company’s stock.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG opened at $536.55 on Tuesday. Intuitive Surgical, Inc. has a 1 year low of $304.50 and a 1 year high of $552.00. The firm has a 50-day moving average of $505.63 and a 200 day moving average of $465.19. The stock has a market cap of $191.11 billion, a P/E ratio of 86.26, a price-to-earnings-growth ratio of 5.39 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.32. The firm had revenue of $2.04 billion during the quarter, compared to analyst estimates of $2.01 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. Research analysts expect that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ISRG has been the topic of a number of recent research reports. Oppenheimer reaffirmed a “market perform” rating on shares of Intuitive Surgical in a research note on Friday, October 18th. The Goldman Sachs Group set a $604.00 price target on Intuitive Surgical in a research report on Friday, October 18th. JPMorgan Chase & Co. boosted their price objective on Intuitive Surgical from $495.00 to $575.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Robert W. Baird raised their target price on shares of Intuitive Surgical from $503.00 to $565.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Finally, Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their price target for the company from $380.00 to $510.00 in a report on Friday, August 2nd. One analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $524.61.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.